The use of Atypical antipsychotics in French psychiatric hospitals

Pharmacy World and Science

Volumn 29, Issue 5, 2007, Pages 551-556

  Bret, Marie Christine ^a   Bret, Pierre ^a   Pariente, Antoine ^b   Fourier Réglat, Annie ^b  

^a CENTRE HOSPITALIER CHARLES PERRENS   (France)

^b UNIVERSITÉ DE BORDEAUX   (France)

Author keywords

Atypical antipsychotics; France; Guidelines; Hospital pharmacy; Prescribing; Psychiatry

Indexed keywords

AMISULPRIDE; ANTIDEPRESSANT AGENT; ANTIPARKINSON AGENT; ANXIOLYTIC AGENT; ARTIFICIAL TEAR; ATYPICAL ANTIPSYCHOTIC AGENT; CARDIOVASCULAR AGENT; CHOLINERGIC RECEPTOR BLOCKING AGENT; CLOZAPINE; HYPNOTIC AGENT; LAXATIVE; MOOD STABILIZER; NEUROLEPTIC AGENT; OLANZAPINE; PSYCHOTROPIC AGENT; RISPERIDONE; SEDATIVE AGENT;

ADULT; AGE DISTRIBUTION; AGED; ARTICLE; BIPOLAR DISORDER; CLINICAL FEATURE; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DOSE RESPONSE; DRUG MARKETING; DRUG MEGADOSE; DRUG USE; FEMALE; FRANCE; HEALTH SURVEY; HOSPITAL PATIENT; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL PRACTICE; MEDICAL SOCIETY; MENTAL HOSPITAL; OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; PHARMACIST; PRESCRIPTION; PSYCHOSIS; SEX DIFFERENCE; TREATMENT INDICATION;

ADULT; AGE FACTORS; ANTIMANIC AGENTS; ANTIPARKINSON AGENTS; ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; BIPOLAR DISORDER; CLOZAPINE; CROSS-SECTIONAL STUDIES; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG THERAPY, COMBINATION; FEMALE; FRANCE; HOSPITALS, PSYCHIATRIC; HUMANS; MALE; MENTAL DISORDERS; MIDDLE AGED; PHYSICIAN'S PRACTICE PATTERNS; PSYCHOTIC DISORDERS; RISPERIDONE; SEX FACTORS; SULPIRIDE;

EID: 34548598172     PISSN: 09281231     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11096-007-9107-1     Document Type: Article

References (20)

1. American Psychiatric Association (APA). Practice guideline for the treatment of patients with schizophrenia. Am J Psych 1997;154(Suppl 4)
2. Andem (National Agency for Development of Medical Evaluation) Recommendations and medical references: neuroleptic prescriptions. Concours Medical 1997;119:1441-5, 1609-14, 1767-73
3. Augry F, Esvan M. Prescription of atypical antipsychotics in a psychiatric hospital. Nervure 2001;IV: 7-13
4. Bret P, Bonnet F, Bret MC, Jaffre A. Use of atypical antipsychotics in Charles Perrens psychiatric hospital (Bordeaux): prescribing practices for Amisulpride, Clozapine, Olanzapine and Risperidone. Encephale 2002;XXVIII:329-42
5. Brunot A, Lachaux B, Sontag H, Casadebaig F, Philippe A, Rouillon F et al. Pharmaco-epidemiological study on antipsychotic drug prescription in French psychiatry: patient characteristics, antipsychotic treatment and care management for schizophrenia. Encephale 2002;XXVIII: 129-38
6. Collaborative Working Group on Clinical Trial Evaluations. Adverse effects of the atypical antipsychotics. J Clin Psychiatry 1998;59(suppl 12)
7. College of Quebec Clinicians. Schizophrenia treatment [Guidelines : Treating Schizoprenia] (June 1999). (on http://www.cmq.org/uploadedfiles/ lignestraitementsschizophrenieang99.pdf )
8. Consensus Conference (THE). Strategies for long-term therapy of patients with schizophrenia. French federation of psychiatry, national agency for the development of medical evaluation and national union of friends and families of psychiatric patients (eds), Paris, 13 et 14 January 1994, 32 pp
9. Fabre Almaric E. Psychotropic drug prescriptions and corrector agent prescriptions in a French psychiatric hospital. Pharmacie Hospitaliere Française 1998;124:69-77
10. Fourrier A, Gasquet I, Allicar MP, Bouhassira M, Lepine JP, Begaud B. Patterns of neuroleptic drug prescription: a national cross-sectional survey of a random sample of French psychiatrists. Br J Clin Pharmacol 2000; 49:80-6
11. Gury C, Berchot F, Fabre C, Surugue J, Welcomme N. Analysis of neuroleptics prescriptions in five specialized hospitals: comparison between hospital prescriptions and discharge prescriptions. L'information psychiatrique 2002;8:954-63
12. ICD 10/CIM 10. The ICD-10 Classification of Mental and Behavioural Disorders Clinical descriptions and diagnostic guidelines. 10th revision. Masson, 1994
13. Lecrubier Y, Azorin M, Bottai T, Dalery J, Garreau G, Lemperiere T. Consensus on the practical use of Amisulpride, an atypical antipsychotic, in the treatment of schizophrenia. Neuropsychobiology 2001;44:41-6
14. Lehman AF, Steiwachs DM and the Co-investigators of the Port Project. Translating research into practice: the Schizophrenia Patient Outcomes Research Team (PORT). Treatment Recommendations. Schizophr Bull 1998;24(1):1-10
15. Leucht S, Pitschel-Walz G, Abraham D, Kissling W. Efficacy and extrapyramidal side effects of the new antipsychotics olanzapine, quetiapine, risperidone and sertindole compared to conventional antipsychotics and placebo. A meta-analysis of randomized controlled trials. Schizophren Res 1998;35:51-68
16. McEvoy JP, Scheifler PL, Frances A. The Expert Consensus Guideline series: treatment of schizophrenia. J Clin Psychiatr 1999;60(suppl 11)
17. Miller AL, Chiles JA, Chiles JK, Crismon ML, Rush AJ, Shon SP. The Texas Medication Algorithm Project (TMAP): Schizophrenia algorithms. J Clin Psychiatr 1999; 60:649-657
18. Rouillon F, Lachaux B, Fender P, Moreau Defarges T, Richard A, Chicoye A. Pharmaco-repidemiological study of risperidone prescription. La Lettre du Pharmacologue 2000;7:170-5
19. Taylor D, Mc Connell D, Mc Connell H, Abel K, Kervin R. The bethlem and maudsley NHS trust: prescribing guidelines., 5th ed., London: Martin Dunitz; 1999
20. Working Group for the Canadian Psychiatric Association and the Canadian alliance for Research on Schizophrenia. Canadian clinical practice guidelines for the treatment of schizophrenia. Can J Psychiatry 1998;43(suppl. 2)